Patents by Inventor Dan V. Mourich
Dan V. Mourich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11911403Abstract: The present disclosure relates to antisense oligomers and related compositions and methods for increasing the expression of functional human type VII collagen and methods for treating dystrophic epidermolysis bullosa and related disorders and relates to inducing exclusion of exon 80 in human type VII collagen mRNA.Type: GrantFiled: October 26, 2020Date of Patent: February 27, 2024Assignee: Sarepta Therapeutics, Inc.Inventor: Dan V. Mourich
-
Publication number: 20210283170Abstract: Methods for treatment of lymphocyte-related diseases and conditions, such as cancer and automimmune diseases, are provided. The methods comprise administration of an effective amount of an oligomer to a patient in need thereof, wherein the oligomer comprises, inter alia, at least one intersubunit linkage having the following structure: wherein R1, L1, X, Y and Z are as defined herein.Type: ApplicationFiled: April 30, 2021Publication date: September 16, 2021Inventors: Dan V. Mourich, Gunnar J. Hanson, Frederick Joseph Schnell, Johannes Christian Dworzak
-
Publication number: 20210161922Abstract: The present disclosure relates to antisense oligomers and related compositions and methods for increasing the expression of functional human type VII collagen and methods for treating dystrophic epidermolysis bullosa and related disorders and relates to inducing exclusion of exon 80 in human type VII collagen mRNA.Type: ApplicationFiled: October 26, 2020Publication date: June 3, 2021Inventor: Dan V. Mourich
-
Patent number: 11020417Abstract: Methods for treatment of lymphocyte-related diseases and conditions, such as cancer and automimmune diseases, are provided. The methods comprise administration of an effective amount of an oligomer to a patient in need thereof, wherein the oligomer comprises, inter alia, at least one intersubunit linkage having the following structure: wherein R1, L1, X, Y and Z are as defined herein.Type: GrantFiled: June 3, 2016Date of Patent: June 1, 2021Assignee: Sarepta Therapeutics, IncInventors: Dan V. Mourich, Gunnar J. Hanson, Frederick Joseph Schnell, Johannes Christian Dworzak
-
Patent number: 10849917Abstract: The present disclosure relates to antisense oligomers and related compositions and methods for increasing the expression of functional human type VII collagen and methods for treating dystrophic epidermolysis bullosa and related disorders and relates to inducing exclusion of exon 80 in human type VII collagen mRNA.Type: GrantFiled: June 1, 2016Date of Patent: December 1, 2020Assignee: SAREPTA THERAPEUTICS, INC.Inventor: Dan V. Mourich
-
Publication number: 20190201425Abstract: The present disclosure relates to antisense oligomers and related compositions and methods for increasing the expression of functional human type VII collagen and methods for treating dystrophic epidermolysis bullosa and related disorders and relates to inducing exclusion of exon 80 in human type VII collagen mRNA.Type: ApplicationFiled: June 1, 2016Publication date: July 4, 2019Inventor: Dan V. Mourich
-
Publication number: 20180161359Abstract: Methods for treatment of lymphocyte-related diseases and conditions, such as cancer and automimmune diseases, are provided. The methods comprise administration of an effective amount of an oligomer to a patient in need thereof, wherein the oligomer comprises, inter alia, at least one intersubunit linkage having the following structure: wherein R1, L1, X, Y and Z are as defined herein.Type: ApplicationFiled: June 3, 2016Publication date: June 14, 2018Inventors: Dan V. Mourich, Gunnar J. Hanson, Frederick Joseph Schnell, Johannes Christian Dworzak
-
Patent number: 9487786Abstract: A method and compound for suppressing an immune response in a mammalian subject, for the treatment or prevention of an autoimmune condition or transplantation rejection are disclosed. The compound is an antisense oligonucleotide analog compound having a targeting sequence complementary to a preprocessed CTLA-4 mRNA region identified by SEQ ID NO: 22 in SEQ ID NO: 1, spanning the splice junction between intron 1 and exon 2 of the preprocessed mRNA of the subject. The compound is effective, when administered to a subject, to form within host cells, a heteroduplex structure (i) composed of the preprocessed CTLA-4 mRNA and the oligonucleotide compound, (ii) characterized by a Tm of dissociation of at least 45° C., and (iii) resulting in an increased ratio of processed mRNA encoding ligand-independent CTLA-4 to processed mRNA encoding full-length CTLA-4.Type: GrantFiled: December 23, 2014Date of Patent: November 8, 2016Assignee: SAREPTA THERAPEUTICS, INC.Inventors: Dan V. Mourich, Patrick L. Iversen, Dwight D. Weller
-
Patent number: 9238042Abstract: Provided are antisense oligonucleotides and other agents that target and modulate IL-17 and/or IL-23 signaling activity in a cell, compositions that comprise the same, and methods of use thereof. Also provided are animal models for identifying agents that modulate 17 and/or IL-23 signaling activity.Type: GrantFiled: May 13, 2011Date of Patent: January 19, 2016Assignee: Sarepta Therapeutics, Inc.Inventors: Frederick J. Schnell, Patrick L. Iversen, Dan V. Mourich, Gunnar J. Hanson
-
Publication number: 20150184165Abstract: A method and compound for suppressing an immune response in a mammalian subject, for the treatment or prevention of an autoimmune condition or transplantation rejection are disclosed. The compound is an antisense oligonucleotide analog compound having a targeting sequence complementary to a preprocessed CTLA-4 mRNA region identified by SEQ ID NO: 22 in SEQ ID NO: 1, spanning the splice junction between intron 1 and exon 2 of the preprocessed mRNA of the subject. The compound is effective, when administered to a subject, to form within host cells, a heteroduplex structure (i) composed of the preprocessed CTLA-4 mRNA and the oligonucleotide compound, (ii) characterized by a Tm of dissociation of at least 45° C., and (iii) resulting in an increased ratio of processed mRNA encoding ligand-independent CTLA-4 to processed mRNA encoding full-length CTLA-4.Type: ApplicationFiled: December 23, 2014Publication date: July 2, 2015Inventors: Dan V. Mourich, Patrick L. Iversen, Dwight D. Weller
-
Patent number: 8933216Abstract: A method and compound for suppressing an immune response in a mammalian subject, for the treatment or prevention of an autoimmune condition or transplantation rejection are disclosed. The compound is an antisense oligonucleotide analog compound having a targeting sequence complementary to a preprocessed CTLA-4 mRNA region identified by SEQ ID NO: 22 in SEQ ID NO: 1, spanning the splice junction between intron 1 and exon 2 of the preprocessed mRNA of the subject. The compound is effective, when administered to a subject, to form within host cells, a heteroduplex structure (i) composed of the preprocessed CTLA-4 mRNA and the oligonucleotide compound, (ii) characterized by a Tm of dissociation of at least 45° C., and (iii) resulting in an increased ratio of processed mRNA encoding ligand-independent CTLA-4 to processed mRNA encoding full-length CTLA-4.Type: GrantFiled: July 11, 2013Date of Patent: January 13, 2015Assignee: Sarepta Therapeutics, Inc.Inventors: Dan V. Mourich, Patrick L. Iversen, Dwight D. Weller
-
Publication number: 20140287983Abstract: Provided are methods and compositions, including topical compositions, for inducing tolerance to a sensitizing agent known to provoke contact hypersensitivity in a subject. Included are methods of topically applying to the subject an effective amount of an antisense composition targeting the start site or splice site of a CFLAR mRNA.Type: ApplicationFiled: October 25, 2013Publication date: September 25, 2014Applicant: SAREPTA THERAPEUTICS, INC.Inventors: Dan V. Mourich, Nikki B. Marshall, Patrick L. Iversen
-
Publication number: 20140194612Abstract: A method and compound for suppressing an immune response in a mammalian subject, for the treatment or prevention of an autoimmune condition or transplantation rejection are disclosed. The compound is an antisense oligonucleotide analog compound having a targeting sequence complementary to a preprocessed CTLA-4 mRNA region identified by SEQ ID NO: 22 in SEQ ID NO: 1, spanning the splice junction between intron 1 and exon 2 of the preprocessed mRNA of the subject. The compound is effective, when administered to a subject, to form within host cells, a heteroduplex structure (i) composed of the preprocessed CTLA-4 mRNA and the oligonucleotide compound, (ii) characterized by a Tm of dissociation of at least 45° C., and (iii) resulting in an increased ratio of processed mRNA encoding ligand-independent CTLA-4 to processed mRNA encoding full-length CTLA-4.Type: ApplicationFiled: July 11, 2013Publication date: July 10, 2014Applicant: Sarepta Therapeutics, Inc.Inventors: Dan V. Mourich, Patrick L. Iversen, Dwight D. Weller
-
Patent number: 8592386Abstract: Provided are methods and compositions, including topical compositions, for inducing tolerance to a sensitizing agent known to provoke contact hypersensitivity in a subject. Included are methods of topically applying to the subject an effective amount of an antisense composition targeting the start site or splice site of a CFLAR mRNA.Type: GrantFiled: December 17, 2009Date of Patent: November 26, 2013Assignee: Sarepta Therapeutics, Inc.Inventors: Dan V. Mourich, Nikki B. Marshall, Patrick L. Iversen
-
Patent number: 8501704Abstract: Provided are methods and antisense oligonucleotide analogs for suppressing an immune response in a mammalian subject, for the treatment or prevention of an autoimmune condition or transplantation rejection. The oligonucleotide analogs provided herein comprise a targeting sequence complementary to a preprocessed CTLA-4 mRNA region that spans the splice junction between intron 1 and exon 2 of the preprocessed CTLA-4 mRNA. Also provided are methods of use, in which the oligonucleotides are effective, when administered to a subject, to form within host cells, a heteroduplex structure (i) composed of the preprocessed CTLA-4 mRNA and the oligonucleotide compound, (ii) characterized by a Tm of dissociation of at least 45° C., and (iii) resulting in an increased ratio of processed mRNA encoding ligand-independent CTLA-4 to processed mRNA encoding full-length CTLA-4.Type: GrantFiled: November 7, 2008Date of Patent: August 6, 2013Assignee: Sarepta Therapeutics, Inc.Inventors: Dan V. Mourich, Patrick L. Iversen, Dwight D. Weller
-
Patent number: 8415313Abstract: A method and composition for inducing human dendritic cells to a condition of reduced capacity for antigen-specific activation of T cells, and, in mature dendritic cells, increased production of extracellular IL-10 is disclosed. A population of dendritic cells is exposed to a substantially uncharged antisense compound, including partially positively charged, containing 12-40 subunits and a base sequence effective to hybridize to a target region within the sequence identified by SEQ ID NO:9, to form a duplex structure between the compound and transcript having a Tm of at least 45° C. Formation of the duplex blocks expression of full-length CD86 in the cells, which in turn leads to reduced capacity for antigen-specific activation of T cells, and, in mature dendritic cells, increased production of extracellular IL-10.Type: GrantFiled: May 11, 2006Date of Patent: April 9, 2013Assignee: AVI BioPharma, Inc.Inventors: Dan V. Mourich, Patrick L. Iversen, Dwight D. Weller
-
Publication number: 20120027791Abstract: A method and conjugate for selectively killing antigen-activated T cells are disclosed. The conjugate is composed of a substantially uncharged antisense compound targeted against the human cFLIP protein, and a reverse TAT (rTAT) polypeptide coupled covalently to the antisense compound. The rTAT polypeptide is effective to produce selective uptake of the conjugate into antigen-activated T cells, relative to the uptake of the conjugate into non-activated T cells. The cFLIP antisense compound causes activation induced cell death (AICD) of activated lymphocytes. The method is useful in treating transplantation rejection and autoimmune conditions.Type: ApplicationFiled: July 20, 2011Publication date: February 2, 2012Applicant: AVI BIOPHARMA, INC.Inventors: Dan V. Mourich, Hong Mu Moulton, David J. Hinrichs, Patrick L. Iversen
-
Publication number: 20110318382Abstract: An antisense oligonucleotide compound, composition, vaccine and methods for treating a variety of conditions characterized by up-regulation of IL-10 in a mammalian subject are disclosed. The compound (i) is composed of morpholino subunits and phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5? exocyclic carbon of an adjacent subunit, (ii) is capable of uptake by monocytes, lymphocytes, and dendritic cells in a mammalian subject, (iii) contains between 10-40 nucleotide bases, and (iv) has a base sequence effective to hybridize to at least 12 contiguous bases of a target sequence contained in an exon-2 or exon-4 slice site region of human IL-10 pre-mRNA.Type: ApplicationFiled: June 22, 2011Publication date: December 29, 2011Applicant: AVI BIOPHARMA, INC.Inventors: Dan V. Mourich, Patrick L. Iversen
-
Publication number: 20110289608Abstract: Provided are antisense oligonucleotides and other agents that target and modulate IL-17 and/or IL-23 signaling activity in a cell, compositions that comprise the same, and methods of use thereof. Also provided are animal models for identifying agents that modulate 17 and/or IL-23 signaling activity.Type: ApplicationFiled: May 13, 2011Publication date: November 24, 2011Applicant: AVI BIOPHARMA, INC.Inventors: Frederick J. Schnell, Patrick L. Iversen, Dan V. Mourich
-
Patent number: 8008469Abstract: A method and conjugate for selectively killing antigen-activated T cells are disclosed. The conjugate is composed of a substantially uncharged antisense compound targeted against the human cFLIP protein, and a reverse TAT (rTAT) polypeptide coupled covalently to the antisense compound. The rTAT polypeptide is effective to produce selective uptake of the conjugate into antigen-activated T cells, relative to the uptake of the conjugate into non-activated T cells. The cFLIP antisense compound causes activation induced cell death (AICD) of activated lymphocytes. The method is useful in treating transplantation rejection and autoimmune conditions.Type: GrantFiled: November 15, 2007Date of Patent: August 30, 2011Assignee: AVI BioPharma Inc.Inventors: Dan V. Mourich, Hong M. Moulton, David J. Hinrichs, Patrick L. Iversen